Cachexia is a wasting syndrome prevalent in cancer patients (as well as patients with other conditions) that is marked by weight loss, loss of muscle mass, fatigue, and lack of appetite, and is ...

There are certain diseases that can severely impact your weight and muscle mass, leading to significant health challenges.

We also aimed to study whether anemia in COPD is related to presence of cachexia. To test this, we determined in a group of COPD patients the prevalence of anemia and its relationship to body ...

Other symptoms included menorrhagia (one case) and cachexia (two cases). The symptoms recorded for ... Gingival bleeding, corkscrew hairs, and anemia can further aid in distinguishing between the two ...

A nationwide clinical trial shows positive results for cancer patients with this common wasting syndrome. Researchers discovered a drug that safely and effectively helped cancer patients when they ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...

A drug that could reduce the risk of death in cancer patients is showing good promise during its second phase of clinical ...

Pfizer’s cancer cachexia candidate has provided patients with clinically meaningful weight gain in a Phase II trial, with the company sharing aims to start a pivotal programme in 2025.

A total of 187 patients underwent randomization. Of these patients, 40% had non–small-cell lung cancer, 32% had pancreatic cancer, and 29% had colorectal cancer. At 12 weeks, patients in the ...

The experimental drug ponsegromab is a monoclonal antibody that treats the growth factor that leads to the growth of cancer cells, which is called cachexia, Pfizer said in a news release Saturday.

The following is a summary of “Insights on prevalence and incidence of anemia and rapid up-titration of oral heart failure ...